$145.10
▼ -0.3% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?
Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?
Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run
Overview
52-week range
$22
$177
80% of range
Avg surprise (last 2)
+21.2%
Avg reaction (last 1)
-5.3%
0% positive
Latest IV / EM
91%
EM ±3.8% · $148 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.97 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $-3.40 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.51 | — | — | — | — | financials |
| Fri Aug 1, 2025 | Jun/2025 | $-2.13 | $-2.99 | +28.8% | — | — | earnings |
| Thu May 1, 2025 | Mar/2025 | $-2.52 | $-2.92 | +13.7% | — | -5.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.03 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.33 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-3.07 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-9.53 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.62 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.19 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145M | $389M | — | $1.02B | $142M | $108M | — | $1.86B |
| Cost of revenue | $93M | $955M | — | $207M | $119M | $90M | — | $514M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-815M | $-1.39B | — | $-260M | $-907M | $-1.05B | — | $-70M |
| Net income | $-782M | $-1.34B | — | $-200M | $-825M | $-971M | — | $13M |
| EPS (diluted) | $-1.97 | $-3.40 | — | $-0.51 | $-2.13 | $-2.52 | — | $0.03 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.72B | $1.91B | $2.60B | $1.13B | $1.28B | $1.62B | $1.93B | $1.64B |
| Inventory | $280M | $146M | $153M | $332M | $240M | $128M | $117M | $412M |
| Total current assets | $5.82B | $5.77B | $6.54B | $6.60B | $6.17B | $6.77B | $8.10B | $9.67B |
| Total assets | $10.96B | $11.49B | $12.34B | $12.13B | $12.01B | $12.70B | $14.14B | $15.80B |
| Long-term debt | $591M | $590M | $590M | — | — | — | — | — |
| Total liabilities | $4.20B | $4.08B | $3.69B | $2.81B | $2.61B | $2.64B | $3.24B | $3.88B |
| Total equity | $6.76B | $7.41B | $8.65B | $9.33B | $9.40B | $10.07B | $10.90B | $11.93B |